Prostate cancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis, according to ...

A cancer diagnosis is scary. Some doctors say it’s time to rename low-grade prostate cancer to eliminate the alarming C-word. Cancer cells develop in nearly all prostates as men age, and most prostate ...

A new study reveals that some men who are diagnosed with "Grade Group one" (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell ...

Dr. Neal Patel says biopsy results may not fully capture prostate cancer risk, stressing that PSA, stage and disease volume should also guide treatment. Biopsy results alone may not fully capture the ...

Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate ...

Prostate-specific antigen (PSA) screening for prostate cancer (PCa) remains highly controversial, largely because it is unclear whether the primary benefits of reducing rates of metastases and cancer ...

A new study reveals that some men who are diagnosed with “Grade Group one” (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell ...

GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...

Effective cancer screening protocols can dramatically alter outcomes for patients. Prostate cancer, for example, has been one of the most common cancers among men in the United States for decades. In ...